Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Sage wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
2 of 2 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Letrozole and Sage have evidence — compare verdict strength side-by-side.
Indication-specific and clinician-directed. Ovulation induction: 2.5-7.5 mg once daily for 5 days early in the cycle (typically days 3-7). Breast cancer: 2.5 mg once daily continuously. Off-label male use mirrors 2.5 mg once to a few times weekly (NOT daily) titrated to testosterone/estradiol — a prescription drug, not an approved supplement regimen.
any
Oral letrozole 2.5 mg tablet (Femara / generic)
300–600 mg standardized extract daily
With breakfast, With dinner (split dosing)
Standardized extract (300–600 mg, 2.5% rosmarinic acid)
Per cycle (days 3-7 dosing)
Weeks to months
Months to years
Months to years
4–8 weeks
4–8 weeks
4–8 weeks
8–12 weeks
Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
The New England journal of medicine (2014) · Rct · n=750
Double-blind multicenter RCT of 750 women with PCOS randomized to letrozole or clomiphene for up to five cycles, primary outcome live birth
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Cochrane Database of Systematic Reviews (2022) · Meta analysis
Cochrane systematic review of 41 RCTs (6522 women); letrozole was used in all trials
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.
Cochrane Database of Systematic Reviews (2018) · Meta analysis
Earlier Cochrane systematic review including 42 RCTs (7935 women); letrozole was used in all studies
Systematic review of clinical trials assessing pharmacological properties of Salvia species on memory, cognitive impairment and Alzheimer's disease.
CNS Neuroscience & Therapeutics (2014) · Systematic review
Multiple clinical trials demonstrated improvements in memory and attention in healthy young adults following acute and chronic Salvia officinalis or Salvia lavandulaefolia administration.
Exploring the therapeutic impact of Salvia officinalis on lipid and oxidative stress markers in patients with polycystic ovary syndrome - a randomized placebo-controlled clinical trial.
BMC Complementary Medicine and Therapies (2025) · Rct · n=60
Women with PCOS receiving Salvia officinalis extract showed significant reductions in total cholesterol, LDL cholesterol, and triglycerides compared to the placebo group.
Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease
J Clin Pharm Ther (2003) · Rct · n=42
Significant improvement in ADAS-cog and CDR-SB scores vs placebo (P<0.003)
Based on multiple RCTs showing improvements in word recall, working memory, and attention. Effects varied by specific cognitive domain and population. Most studies used standardized extracts.
AI-estimated from published studies. Interpret as directional guidance.
Sage has a higher evidence score (6/10 vs 5/10) and wins in 2 of 3 categories.
No known interactions between Letrozole and Sage have been documented in our database. However, always consult a healthcare provider before combining supplements.